Does the media favor DMRA or CGON?

In the previous week, CG Oncology had 6 more articles in the media than Damora Therapeutics, Inc. Common Stock. MarketBeat recorded 8 mentions for CG Oncology and 2 mentions for Damora Therapeutics, Inc. Common Stock. CG Oncology's average media sentiment score of 0.56 beat Damora Therapeutics, Inc. Common Stock's score of 0.29 indicating that CG Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Damora Therapeutics, Inc. Common Stock 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CG Oncology 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, ORKA or DMRA?

Oruka Therapeutics is trading at a lower price-to-earnings ratio than Damora Therapeutics, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Oruka Therapeutics N/A N/A -$105.43M -$2.03 N/A Damora Therapeutics, Inc. Common Stock N/A N/A -$209.84M -$3.37 N/A

Is ORKA or DMRA more profitable?

Oruka Therapeutics' return on equity of -21.65% beat Damora Therapeutics, Inc. Common Stock's return on equity. Company Net Margins Return on Equity Return on Assets Oruka Therapeutics N/A -21.65% -20.88% Damora Therapeutics, Inc. Common Stock N/A -176.39% -77.86%

Which has preferable valuation and earnings, DMRA or SRRK?

Scholar Rock is trading at a lower price-to-earnings ratio than Damora Therapeutics, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Damora Therapeutics, Inc. Common Stock N/A N/A -$209.84M -$3.37 N/A Scholar Rock N/A N/A -$377.94M -$3.45 N/A

Is DMRA or SRRK more profitable?

Scholar Rock's return on equity of -160.19% beat Damora Therapeutics, Inc. Common Stock's return on equity. Company Net Margins Return on Equity Return on Assets Damora Therapeutics, Inc. Common Stock N/A -176.39% -77.86% Scholar Rock N/A -160.19% -87.18%

Does the media favor DMRA or SRRK?

In the previous week, Scholar Rock had 30 more articles in the media than Damora Therapeutics, Inc. Common Stock. MarketBeat recorded 32 mentions for Scholar Rock and 2 mentions for Damora Therapeutics, Inc. Common Stock. Scholar Rock's average media sentiment score of 0.78 beat Damora Therapeutics, Inc. Common Stock's score of 0.29 indicating that Scholar Rock is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Damora Therapeutics, Inc. Common Stock 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Scholar Rock 13 Very Positive mention(s) 5 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Damora Therapeutics, Inc. Common Stock (DMRA) Competitors

$22.59 -0.19 (-0.83%)

As of 09/18/2026 04:00 PM Eastern

Compare

DMRA vs. CGON, ORKA, SRRK, MIRM, and TVTX

Should you buy Damora Therapeutics, Inc. Common Stock stock or one of its competitors? Damora Therapeutics, Inc. Common Stock's main competitors and comparable companies include CG Oncology (CGON), Oruka Therapeutics (ORKA), Scholar Rock (SRRK), Mirum Pharmaceuticals (MIRM), and Travere Therapeutics (TVTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Damora Therapeutics, Inc. Common Stock compare to CG Oncology?

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) and CG Oncology (NASDAQ:CGON) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, earnings, risk, analyst recommendations, valuation and institutional ownership.

CG Oncology has higher revenue and earnings than Damora Therapeutics, Inc. Common Stock. CG Oncology is trading at a lower price-to-earnings ratio than Damora Therapeutics, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Damora Therapeutics, Inc. Common Stock	N/A	N/A	-$209.84M	-$3.37	N/A
CG Oncology	$4.04M	1,637.21	-$160.99M	-$2.69	N/A

In the previous week, CG Oncology had 6 more articles in the media than Damora Therapeutics, Inc. Common Stock. MarketBeat recorded 8 mentions for CG Oncology and 2 mentions for Damora Therapeutics, Inc. Common Stock. CG Oncology's average media sentiment score of 0.56 beat Damora Therapeutics, Inc. Common Stock's score of 0.29 indicating that CG Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Damora Therapeutics, Inc. Common Stock	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
CG Oncology	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Damora Therapeutics, Inc. Common Stock currently has a consensus price target of $44.00, suggesting a potential upside of 94.78%. CG Oncology has a consensus price target of $87.78, suggesting a potential upside of 17.63%. Given Damora Therapeutics, Inc. Common Stock's stronger consensus rating and higher probable upside, equities research analysts plainly believe Damora Therapeutics, Inc. Common Stock is more favorable than CG Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Damora Therapeutics, Inc. Common Stock	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.00
CG Oncology	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

Damora Therapeutics, Inc. Common Stock has a net margin of 0.00% compared to CG Oncology's net margin of -3,602.68%. CG Oncology's return on equity of -25.20% beat Damora Therapeutics, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Damora Therapeutics, Inc. Common Stock	N/A	-176.39%	-77.86%
CG Oncology	-3,602.68%	-25.20%	-23.98%

14.2% of Damora Therapeutics, Inc. Common Stock shares are held by institutional investors. Comparatively, 26.6% of CG Oncology shares are held by institutional investors. 0.4% of Damora Therapeutics, Inc. Common Stock shares are held by insiders. Comparatively, 4.8% of CG Oncology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Damora Therapeutics, Inc. Common Stock has a beta of 1.46, suggesting that its stock price is 46% more volatile than the broader market. Comparatively, CG Oncology has a beta of 0.24, suggesting that its stock price is 76% less volatile than the broader market.

Summary

CG Oncology beats Damora Therapeutics, Inc. Common Stock on 10 of the 16 factors compared between the two stocks.

How does Damora Therapeutics, Inc. Common Stock compare to Oruka Therapeutics?

Oruka Therapeutics (NASDAQ:ORKA) and Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, profitability, earnings, institutional ownership, valuation, media sentiment and dividends.

In the previous week, Oruka Therapeutics had 11 more articles in the media than Damora Therapeutics, Inc. Common Stock. MarketBeat recorded 13 mentions for Oruka Therapeutics and 2 mentions for Damora Therapeutics, Inc. Common Stock. Damora Therapeutics, Inc. Common Stock's average media sentiment score of 0.29 beat Oruka Therapeutics' score of 0.26 indicating that Damora Therapeutics, Inc. Common Stock is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oruka Therapeutics	5 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Damora Therapeutics, Inc. Common Stock	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Oruka Therapeutics currently has a consensus target price of $133.00, suggesting a potential upside of 40.06%. Damora Therapeutics, Inc. Common Stock has a consensus target price of $44.00, suggesting a potential upside of 94.78%. Given Damora Therapeutics, Inc. Common Stock's stronger consensus rating and higher probable upside, analysts clearly believe Damora Therapeutics, Inc. Common Stock is more favorable than Oruka Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oruka Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82
Damora Therapeutics, Inc. Common Stock	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.00

Oruka Therapeutics is trading at a lower price-to-earnings ratio than Damora Therapeutics, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oruka Therapeutics	N/A	N/A	-$105.43M	-$2.03	N/A
Damora Therapeutics, Inc. Common Stock	N/A	N/A	-$209.84M	-$3.37	N/A

Oruka Therapeutics has a beta of -0.34, meaning that its stock price is 134% less volatile than the broader market. Comparatively, Damora Therapeutics, Inc. Common Stock has a beta of 1.46, meaning that its stock price is 46% more volatile than the broader market.

56.4% of Oruka Therapeutics shares are owned by institutional investors. Comparatively, 14.2% of Damora Therapeutics, Inc. Common Stock shares are owned by institutional investors. 23.5% of Oruka Therapeutics shares are owned by company insiders. Comparatively, 0.4% of Damora Therapeutics, Inc. Common Stock shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Oruka Therapeutics' return on equity of -21.65% beat Damora Therapeutics, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oruka Therapeutics	N/A	-21.65%	-20.88%
Damora Therapeutics, Inc. Common Stock	N/A	-176.39%	-77.86%

Summary

Oruka Therapeutics beats Damora Therapeutics, Inc. Common Stock on 8 of the 14 factors compared between the two stocks.

How does Damora Therapeutics, Inc. Common Stock compare to Scholar Rock?

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) and Scholar Rock (NASDAQ:SRRK) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, risk, valuation, institutional ownership, media sentiment, profitability and dividends.

Scholar Rock's return on equity of -160.19% beat Damora Therapeutics, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Damora Therapeutics, Inc. Common Stock	N/A	-176.39%	-77.86%
Scholar Rock	N/A	-160.19%	-87.18%

Scholar Rock is trading at a lower price-to-earnings ratio than Damora Therapeutics, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Damora Therapeutics, Inc. Common Stock	N/A	N/A	-$209.84M	-$3.37	N/A
Scholar Rock	N/A	N/A	-$377.94M	-$3.45	N/A

Damora Therapeutics, Inc. Common Stock has a beta of 1.46, meaning that its share price is 46% more volatile than the broader market. Comparatively, Scholar Rock has a beta of 0.67, meaning that its share price is 33% less volatile than the broader market.

Damora Therapeutics, Inc. Common Stock currently has a consensus price target of $44.00, suggesting a potential upside of 94.78%. Scholar Rock has a consensus price target of $66.00, suggesting a potential upside of 41.48%. Given Damora Therapeutics, Inc. Common Stock's higher possible upside, research analysts clearly believe Damora Therapeutics, Inc. Common Stock is more favorable than Scholar Rock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Damora Therapeutics, Inc. Common Stock	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.00
Scholar Rock	2 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	4 Strong Buy rating(s)	3.00

In the previous week, Scholar Rock had 30 more articles in the media than Damora Therapeutics, Inc. Common Stock. MarketBeat recorded 32 mentions for Scholar Rock and 2 mentions for Damora Therapeutics, Inc. Common Stock. Scholar Rock's average media sentiment score of 0.78 beat Damora Therapeutics, Inc. Common Stock's score of 0.29 indicating that Scholar Rock is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Damora Therapeutics, Inc. Common Stock	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Scholar Rock	13 Very Positive mention(s)	5 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

14.2% of Damora Therapeutics, Inc. Common Stock shares are held by institutional investors. Comparatively, 91.1% of Scholar Rock shares are held by institutional investors. 0.4% of Damora Therapeutics, Inc. Common Stock shares are held by company insiders. Comparatively, 10.3% of Scholar Rock shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Scholar Rock beats Damora Therapeutics, Inc. Common Stock on 7 of the 13 factors compared between the two stocks.

How does Damora Therapeutics, Inc. Common Stock compare to Mirum Pharmaceuticals?

Mirum Pharmaceuticals (NASDAQ:MIRM) and Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, media sentiment, profitability, risk, institutional ownership and analyst recommendations.

In the previous week, Mirum Pharmaceuticals had 6 more articles in the media than Damora Therapeutics, Inc. Common Stock. MarketBeat recorded 8 mentions for Mirum Pharmaceuticals and 2 mentions for Damora Therapeutics, Inc. Common Stock. Mirum Pharmaceuticals' average media sentiment score of 0.62 beat Damora Therapeutics, Inc. Common Stock's score of 0.29 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mirum Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Damora Therapeutics, Inc. Common Stock	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Mirum Pharmaceuticals has a beta of 0.49, indicating that its share price is 51% less volatile than the broader market. Comparatively, Damora Therapeutics, Inc. Common Stock has a beta of 1.46, indicating that its share price is 46% more volatile than the broader market.

14.2% of Damora Therapeutics, Inc. Common Stock shares are owned by institutional investors. 8.3% of Mirum Pharmaceuticals shares are owned by company insiders. Comparatively, 0.4% of Damora Therapeutics, Inc. Common Stock shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Mirum Pharmaceuticals presently has a consensus price target of $137.31, suggesting a potential upside of 49.53%. Damora Therapeutics, Inc. Common Stock has a consensus price target of $44.00, suggesting a potential upside of 94.78%. Given Damora Therapeutics, Inc. Common Stock's stronger consensus rating and higher possible upside, analysts plainly believe Damora Therapeutics, Inc. Common Stock is more favorable than Mirum Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
Damora Therapeutics, Inc. Common Stock	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.00

Damora Therapeutics, Inc. Common Stock has a net margin of 0.00% compared to Mirum Pharmaceuticals' net margin of -139.18%. Mirum Pharmaceuticals' return on equity of -36.28% beat Damora Therapeutics, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mirum Pharmaceuticals	-139.18%	-36.28%	-8.54%
Damora Therapeutics, Inc. Common Stock	N/A	-176.39%	-77.86%

Mirum Pharmaceuticals has higher revenue and earnings than Damora Therapeutics, Inc. Common Stock. Damora Therapeutics, Inc. Common Stock is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mirum Pharmaceuticals	$521.31M	11.44	-$23.36M	-$14.55	N/A
Damora Therapeutics, Inc. Common Stock	N/A	N/A	-$209.84M	-$3.37	N/A

Summary

Mirum Pharmaceuticals beats Damora Therapeutics, Inc. Common Stock on 9 of the 16 factors compared between the two stocks.

How does Damora Therapeutics, Inc. Common Stock compare to Travere Therapeutics?

Travere Therapeutics (NASDAQ:TVTX) and Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, profitability, institutional ownership, analyst recommendations and media sentiment.

14.2% of Damora Therapeutics, Inc. Common Stock shares are owned by institutional investors. 4.4% of Travere Therapeutics shares are owned by insiders. Comparatively, 0.4% of Damora Therapeutics, Inc. Common Stock shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Travere Therapeutics has a beta of 1.05, suggesting that its stock price is 5% more volatile than the broader market. Comparatively, Damora Therapeutics, Inc. Common Stock has a beta of 1.46, suggesting that its stock price is 46% more volatile than the broader market.

Damora Therapeutics, Inc. Common Stock has a net margin of 0.00% compared to Travere Therapeutics' net margin of -7.35%. Travere Therapeutics' return on equity of -55.15% beat Damora Therapeutics, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Travere Therapeutics	-7.35%	-55.15%	-6.88%
Damora Therapeutics, Inc. Common Stock	N/A	-176.39%	-77.86%

Travere Therapeutics has higher revenue and earnings than Damora Therapeutics, Inc. Common Stock. Travere Therapeutics is trading at a lower price-to-earnings ratio than Damora Therapeutics, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Travere Therapeutics	$490.73M	12.06	-$25.55M	-$0.46	N/A
Damora Therapeutics, Inc. Common Stock	N/A	N/A	-$209.84M	-$3.37	N/A

In the previous week, Travere Therapeutics had 35 more articles in the media than Damora Therapeutics, Inc. Common Stock. MarketBeat recorded 37 mentions for Travere Therapeutics and 2 mentions for Damora Therapeutics, Inc. Common Stock. Travere Therapeutics' average media sentiment score of 0.34 beat Damora Therapeutics, Inc. Common Stock's score of 0.29 indicating that Travere Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Travere Therapeutics	16 Very Positive mention(s)	7 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Damora Therapeutics, Inc. Common Stock	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Travere Therapeutics currently has a consensus target price of $68.00, suggesting a potential upside of 8.35%. Damora Therapeutics, Inc. Common Stock has a consensus target price of $44.00, suggesting a potential upside of 94.78%. Given Damora Therapeutics, Inc. Common Stock's stronger consensus rating and higher probable upside, analysts clearly believe Damora Therapeutics, Inc. Common Stock is more favorable than Travere Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Travere Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Damora Therapeutics, Inc. Common Stock	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.00

Summary

Travere Therapeutics beats Damora Therapeutics, Inc. Common Stock on 9 of the 16 factors compared between the two stocks.

Get Damora Therapeutics, Inc. Common Stock News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DMRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DMRA vs. The Competition

Export

Metric	Damora Therapeutics, Inc. Common Stock	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.39B	$3.90B	$7.24B	$13.19B
Dividend Yield	N/A	3.64%	2.57%	12.81%
P/E Ratio	-6.70	14.23	275.49	25.40
Price / Sales	N/A	1,419.61	646.01	89.45
Price / Cash	N/A	108.90	76.25	51.42
Price / Book	-0.21	15.45	10.46	6.33
Net Income	-$209.84M	-$22.86M	$3.49B	$358.33M
7 Day Performance	-19.61%	-1.21%	0.59%	1.12%
1 Month Performance	-25.47%	-3.29%	-1.74%	-2.39%
1 Year Performance	687.11%	37.74%	18.13%	5.35%

Damora Therapeutics, Inc. Common Stock Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DMRA Damora Therapeutics, Inc. Common Stock	2.6934 of 5 stars	$22.59 -0.8%	$44.00 +94.8%	+687.1%	$1.39B	N/A	N/A	40	High Trading Volume
CGON CG Oncology	2.8453 of 5 stars	$72.55 -1.7%	$87.78 +21.0%	+102.2%	$6.54B	$4.04M	N/A	142	News Coverage
ORKA Oruka Therapeutics	3.4315 of 5 stars	$92.20 -3.9%	$133.00 +44.3%	+510.7%	$6.35B	N/A	N/A	68	Insider Trade Gap Down
SRRK Scholar Rock	3.6662 of 5 stars	$50.00 -3.6%	$66.00 +32.0%	+51.3%	$6.31B	N/A	N/A	289	Analyst Downgrade Analyst Revision Gap Down High Trading Volume
MIRM Mirum Pharmaceuticals	3.0298 of 5 stars	$93.90 -2.9%	$137.31 +46.2%	+23.5%	$6.28B	$521.31M	N/A	433	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DMRA) was last updated on 9/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Damora Therapeutics, Inc. Common Stock (DMRA) Competitors

DMRA vs. CGON, ORKA, SRRK, MIRM, and TVTX

How does Damora Therapeutics, Inc. Common Stock compare to CG Oncology?

Summary

How does Damora Therapeutics, Inc. Common Stock compare to Oruka Therapeutics?

Summary

How does Damora Therapeutics, Inc. Common Stock compare to Scholar Rock?

Summary

How does Damora Therapeutics, Inc. Common Stock compare to Mirum Pharmaceuticals?

Summary

How does Damora Therapeutics, Inc. Common Stock compare to Travere Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DMRA vs. The Competition

Damora Therapeutics, Inc. Common Stock Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Damora Therapeutics, Inc. Common Stock (DMRA) Competitors

DMRA vs. CGON, ORKA, SRRK, MIRM, and TVTX

How does Damora Therapeutics, Inc. Common Stock compare to CG Oncology?

Which has better valuation & earnings, DMRA or CGON?

Does the media favor DMRA or CGON?

Do analysts rate DMRA or CGON?

Is DMRA or CGON more profitable?

Do insiders and institutionals have more ownership in DMRA or CGON?

Which has more risk and volatility, DMRA or CGON?

Summary

How does Damora Therapeutics, Inc. Common Stock compare to Oruka Therapeutics?

Does the media prefer ORKA or DMRA?

Do analysts rate ORKA or DMRA?

Which has better earnings & valuation, ORKA or DMRA?

Which has more risk & volatility, ORKA or DMRA?

Do institutionals and insiders hold more shares of ORKA or DMRA?

Is ORKA or DMRA more profitable?

Summary

How does Damora Therapeutics, Inc. Common Stock compare to Scholar Rock?

Is DMRA or SRRK more profitable?

Which has preferable valuation and earnings, DMRA or SRRK?

Which has more risk & volatility, DMRA or SRRK?

Do analysts prefer DMRA or SRRK?

Does the media favor DMRA or SRRK?

Do insiders and institutionals believe in DMRA or SRRK?

Summary

How does Damora Therapeutics, Inc. Common Stock compare to Mirum Pharmaceuticals?

Does the media prefer MIRM or DMRA?

Which has more volatility & risk, MIRM or DMRA?

Do insiders & institutionals hold more shares of MIRM or DMRA?

Do analysts prefer MIRM or DMRA?

Is MIRM or DMRA more profitable?

Which has preferable valuation and earnings, MIRM or DMRA?

Summary

How does Damora Therapeutics, Inc. Common Stock compare to Travere Therapeutics?

Do insiders and institutionals hold more shares of TVTX or DMRA?

Which has more volatility and risk, TVTX or DMRA?

Is TVTX or DMRA more profitable?

Which has stronger valuation & earnings, TVTX or DMRA?

Does the media prefer TVTX or DMRA?

Do analysts prefer TVTX or DMRA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DMRA vs. The Competition

Damora Therapeutics, Inc. Common Stock Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools